Recombinant Mutant Human Tumor Necrosis Factor-alpha (TNF-SAM2) Immunotherapy with Ranimustine Chemotherapy and Concurrent Radiation Therapy for Malignant Astrocytomas

Anticancer Research

Volumn 23, Issue 6 A, 2003, Pages 4473-4481

  Fukushima, Takeo ^a   Yamamoto, Masaaki ^a   Oshiro, Shinya ^a   Tsugu, Hitoshi ^a   Hirakawa, Katsuyuki ^a   Soma, Gen Ichiro ^b  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKUSHIMA BUNRI UNIVERSITY   (Japan)

Author keywords

Anaplastic astrocytoma; Chemotherapy; Glioblastoma; Immunotherapy; Recombinant mutant tumor necrosis factor alpha (TNF SAM2)

Indexed keywords

RANIMUSTINE; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ALOPECIA AREATA; ASTROCYTOMA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLIOBLASTOMA; HUMAN; HYPOTENSION; INTERMETHOD COMPARISON; LEUKOPENIA; LIFE EXPECTANCY; MALE; MEDICAL ASSESSMENT; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SKIN MANIFESTATION; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASTROCYTOMA; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NITROSOUREA COMPOUNDS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0344440914     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. In: Astrocytomas: Diagnosis, Treatment, and Biology (Black PM, Schoene WC, and Lampson LA, eds). Boston, Blackwell Scientific Publication, 1993.
2. Yamamoto M, Ueno Y, Hayashi S and Fukushima T: The role of proteolysis in tumor invasiveness in glioblastoma and metastatic brain tumors. Anticancer Res 22: 4265-4268, 2002.
3. Bleehen NM and Stenning SP: A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 64: 769-774, 1991.
4. Anders K, Grabenbauer GG, Schuchardt U, Fahlbusch R, Fietkau R, Sauer R and Krauseneck P: Accelerated radiotherapy with concomitant ACNU/Ara-C for the treatment of malignant glioma. J Neurooncol 48: 63-73, 2000.
5. Brandes AA, Scelzi E, Zampieri P, Rigon A, Rotilio A, Amista P, Berti F and Fiorentino MV: Phase II trial with BCNU plus alpha-interferon in patients with recurrent high-grade gliomas. Am J Clin Oncol 20: 364-367, 1997.
6. Buckner JC, Schomberg PJ, McGinnis WL, Cascino TL, Scheithauer BW, O'Fallon JR, Morton RF, Kuross SA, Mailliard JA, Hatfield AK, Cole JT, Steen PD and Bernath AM: A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 92: 420-433, 2001.
7. Croteau D and Mikkelsen T: Adults with newly diagnosed high-grade gliomas. Curr Treat Options Oncol 2: 507-515, 2001.
8. Durando X, Lemaire JJ, Tortochaux J, Van-Praagh I, Kwiatkowski F, Vincent C, Bailly C, Verrelle P, Irthum B, Chazal J and Bay JO: High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients. Bone Marrow Transplant 31: 559-564, 2003.
9. Green SB, Byar DP, Walker MD, Pistenmaa DA, Alexander EJ, Batzdorf U, Brooks WH, Hunt WE, Mealey JJ, Odom GL, Paoletti P, Ransohoff JI, Robertson JT, Selker RG, Ahapiro WR, Smith KR Jr, Wilson CB and Strike TA: Comparisons of BCNU, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep 67: 121-132, 1983.
10. Hildebrand J, Brihaye J, Wagenknecht L, Michael J and Kenis Y: Combination chemotherapy with CCNU, vincristine, and methotrexate in primary and metastatic brain tumors. Eur J Cancer 11: 585-587, 1975.
11. Brufman G, Halpern J, Sulkes A, Catane R and Biran S: Procarbazine, CCNU, and vincristine (PCV) combination chemotherapy for brain tumors. Oncology 41: 239-241, 1984.
12. Levin VA, Silver P, Hannigan J, Wara WM, Gutin, PH, Davis RL and Wilson CB: Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys, 1990.
13. Medical Research Council Brain Tumor Working Party: Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol 19: 509-518, 2001.
14. Murphy C, Pickles T, Knowling M and Thiesse B: Concurrent modified PCV chemotherapy and radiotherapy in newly diagnosed grade IV astrocytoma. J Neurooncol 57: 215-220, 2002.
15. Fazeny-Dorner B, Veitl M, Wenzel C, Rossler K, Ungersbock K, Dieckmann K, Piribauer M, Hainfellner J and Marosi C: Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme. Br J Cancer 88: 496-501, 2003.
16. Langer CJ, Ruffer J, Rhodes H, Paulus R, Murray K, Movsas B and Curran W: Phase II radiation therapy oncology group trial of weekly paclitaxel and conventional external beam radiation therapy for supratentorial glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51: 113-119, 2001.
17. Stenning SP, Freedman LS and Bleehen NM: An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br J Cancer 56: 89-90, 1987.
18. Fine HA, Dear KB, Loeffler JS, Black PM and Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71: 2585-2597, 1993.
19. Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359: 1011-1018, 2002.
20. Jacobs SK, Wilson DJ, Kornblith PL and Grimm EA: Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. J Neurosurg 64: 743-749, 1986.
21. Yung WKA, Prados M and Levin V: Recombinant beta interferon in patients with reccurent malignant gliomas. J Neurooncol 7: 32, 1989.
22. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N and Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 72: 3666-3670, 1975.
23. Creagan ET, Kovach JS, Moertel CG, Frytak S and Kvols LK: A phase I clinical trial of recombinant human tumor necrosis factor. Cancer 62: 2467-2471, 1988.
24. Creaven PJ, Brenner DE, Cowens JW, Huben RP, Wolf RM, Takita H, Arbuck SG, Razack MS and Proefrock AD: A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. Cancer Chemother Pharmacol 23: 186-191, 1989.
25. Hersh EM, Metch BS, Muggia FM, Brown TD, Whitehead RP, Budd GT, Rinehart JJ, Crawford ED, Bonnet JD and Behrens BC: Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience. J Immunother 10: 426-431, 1991.
26. Kimura K, Taguchi T, Urushizaki I, Ohno R, Abe O, Furue H, Hattori T, Ichihashi H, Inoguchi K, Majima H et al: Phase I study of recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 20: 223-229, 1987.
27. Wiedenmann B, Reichardt P, Rath U, Theilmann L, Schule B, Ho AD, Schlick E, Kempeni J, Hunstein W and Kommerell B: Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas. J Cancer Res Clin Oncol 115: 189-192, 1989.
28. Yang SC, Owen Schaub L, Mendiguren, Rodriguez A, Grimm EA, Hong WK and Roth JA: Combination immunotherapy for non-small cell lung cancer. Results with interleukin-2 and tumor necrosis factor-alpha. J Thorac Cardiovasc Surg 99: 8-12; discussion 12-13, 1990.
29. Eggermont AM, Schraffordt Koops H, Lienard D, Kroon BB, van Geel AN, Hoekstra HJ and Lejeune FJ: Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial [see comments]. J Clin Oncol 14: 2653-2665, 1996.
30. Leist M and Jaattela M: Burning up TNF toxicity for cancer therapy. Nat Med 8: 667-668, 2002.
31. Gatanaga T, Noguchi K, Tanabe Y, Inagawa H, Soma G-I and Mizuno D: Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with less toxicity than conventional rTNFa in vivo. J Biol Resp Modif 8: 278-286, 1989.
32. Ohshiro S, Inagawa H, Soma G-I, Fukushima T and Tomonaga M: Antitumor effect of exogenous/endogenous TNF (EET) therapy with cyclophosphamide on C6 glioma in rat. Cancer Biotherapy 9: 359-367, 1994.
33. Fukushima T, Yamamoto M, Ikeda K, Tsugu H, Kimura H, Soma G and Tomonaga M: Treatment of malignant astrocytomas with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Anticancer Res 18: 3965-3970, 1998.
34. In: Histological Typing of Tumors of the Central Nervous System. Ed. 2 edition. (Kleihues P, Burger PC, and Scheithauer BW. eds.) Berlin, Springer-Verlag, 1993, pp, 11-20,
35. Lodato RF, Feig B, Akimaru K, Soma G-I and Kloostergaard J: Hemodynamic evaluation of recombinant human tumor necrosis factor (TNF)-a, TNF-SAM2 and liposomal TNF-SAM2 in an anesthtized dog model. J Immunother 17: 19-29, 1995.
36. Miller AB, Hoogstraten B, Staquent M, and Winkler A: Reporting results of cancer treatment, Cancer 47: 207-214, 1981.
37. Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA Jr and Shepard HM: Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro, Science 230: 943-945, 1985.
38. Barna BP, Estes ML and Jacobs BA: Human astrocytes proliferate in response to tumor necrosis factor alpha. J Neuroimmunol 30: 239-243, 1990.
39. Merrill JE and Benveniste EN: Cytokines in inflammatory brain lesions: helpful and harmaful. Trends Neurosci 19: 331-338, 1996.
40. Wu PC, Alexander HR, Huang J, Hwu P, Gnant M, Berger AC, Turner E, Wilson O and Libutti SK: In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII). Cancer Res 59: 205-212, 1999.
41. Van Antwerp DJ, Martin SJ, Kafri T, Green DR and Verma IM: Suppression of TNF-alpha-induced apoptosis by NF-kappaB [see comments]. Science 274: 787-789, 1996.
42. Wang CY, Mayo MW and Baldwin AS Jr: TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB [see comments]. Science 274: 784-787, 1996.
43. Hsu H, Shu HB, Pan MG and Goeddel DV: TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84: 299-308, 1996.
44. Barth RJ Jr, Mule JJ, Spiess PJ and Rosenberg SA: Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 173: 647-658, 1991.
45. Van de Wiel PA, Bloksma N, Kuper CF, Hofhuis FM and Willers JM: Macroscopic and microscopic early effects of tumour necrosis factor on murine Meth A sarcoma, and relation to curative activity. J Pathol 157: 65-73, 1989.
46. Nawroth P, Handley D, Matsueda G, De Waal R, Gerlach H, Blohm D and Stern D: Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J Exp Med 168: 637-647, 1988.
47. Clauss M, Murray JC, Vianna M, de Waal R, Thurston G, Nawroth P, Gerlach H, Bach R, Familletti PC and Stern DA: Polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to tumor necrosis factor/cachectin. J Biol Chem 265: 7078-7083, 1990.
48. Sersa G, Willingham V and Milas L: Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy. Int J Cancer 42: 129-134, 1988.
49. Leonard MP, Jeffs RD, Gearhart JP and Coffey DS: Recombinant human tumor necrosis factor enhances radiosensitivity and improves animal survival in murine neuroblastoma. J Urol 148: 743-746, 1992.
50. Gridley DS, Archambeau JO, Andres MA, Mao XW, Wright K and Slater JM: Tumor necrosis factor-alpha enhances antitumor effects of radiation against glioma xenografts. Oncol Res 9: 217-227, 1997.
51. Staba M J, Mauceri H J, Kufe DW, Hallahan DE and Weichselbaum RR: Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft. Gene Ther 5: 293-300, 1998.
52. Niranjan A, Moriuchi S, Lunsford LD, Kondziolka D, Flickinger JC, Fellows W, Rajendiran S, Tamura M, Cohen JB and Glorioso JC: Effective treatment of experimental glioblastoma by HSV vector-mediated TNF alpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration. Mol Ther 2: 114-120, 2000.
53. Friedman HS, Kerby T and Calvert HT: Emozolomide and treatment of malignant glioma. Clin Cancer Res 6: 2585-2597, 2000.
54. Gilbert MR, Friedman HS, Kuttesch JF, Prados MD, Olson JJ, Reaman GH and Zaknoen SL: A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neuro Oncol 4: 261-267, 2002.
55. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO and Leyvraz S: Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20: 1375-1382, 2002.
56. Moriuchi, S, Oligino T, Krisky D, Marconi P, Fink D, Cohen J and Glorioso JC: Enhanced tumor cell killing in the presence of ganciclovir by herpes simplex virus type 1 vector-directed coexpression of human tumor necrosis factor-alpha and herpes simplex virus thymidine kinase. Cancer Res 58: 5731-5737, 1998.
57. Yamasaki T, Moritake K, Paine JT, Fukuda M, Ohta F and Naitoh H: Intratumoral administration of tumor necrosis factor-alpha for malignant gliomas-two case reports. Neurol Med Chir Tokyo 34: 216-220, 1994.
58. Yoshida J, Wakabayashi T, Mizuno M, Sugita K, Yoshida T, Hori S, Mori T, Sato T, Karashima A, Kurisu K et al: Clinical effect of intra-arterial tumor necrosis factor-alpha for malignant glioma. J Neurosurg 77: 78-83, 1992.
59. Yamamoto M, Fukushima T, Ueno Y, Hayashi S, Kimura H, Soma G and Tomonaga M: Clinical significance of the expression of endothelial-monocyte activating polypeptide II (EMAPII) in the treatment of glioblastoma with recombinant mutant human tumor necrosis factor-alpha (TNF-SAM2). Anticancer Res 20: 4081-4086, 2000.